Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2026 16:00 ET | Source: Cytokinetics, Incorporated

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of...
June 17, 2026 08:15 ET | Source: Polyrizon Ltd.

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative...
June 17, 2026 07:00 ET | Source: Deep Tech Nation Switzerland

Switzerland extends its lead in the technologies reshaping the global economy

The Swiss Deep Tech Report 2026 ranks Switzerland first in the world for the share of venture capital going to deep tech, ahead of China and the US
June 16, 2026 16:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Attend BIO International Convention 2026

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
June 16, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.
June 16, 2026 08:05 ET | Source: AmMax Bio, Inc.

AmMax Bio Names Biopharmaceutical Executive Travis Read as President and Chief Operating Officer

AmMax Bio, clinical stage targeted oncology ADC company, names biopharmaceutical Executive Travis Read as President and COO.
June 16, 2026 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine
June 16, 2026 05:12 ET | Source: Claret Capital Partners

Claret Capital Partners participates in €130m financing for Inventiva

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.
June 16, 2026 04:52 ET | Source: Claret Capital Partners

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.
June 15, 2026 08:00 ET | Source: Aerska

Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas

DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli...